This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management.
NextGen (NXGN) Implements API to Aid COVID-19 Vaccination
by Zacks Equity Research
NextGen's (NXGN) API is expected to address the unique and evolving reporting needs of various states as they administer the COVID-19 vaccine.
DVA vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. AMED: Which Stock Is the Better Value Option?
Orthofix (OFIX) Launches OSCAR PRO System in the US & Europe
by Zacks Equity Research
Orthofix's (OFIX) latest innovation is expected to drive organic growth in its Global Orthopedics business.
PerkinElmer (PKI) to Boost Immunodiagnostics Unit With Buyout
by Zacks Equity Research
PerkinElmer (PKI) enters into an agreement to acquire IDS, which will enable the former to grow its overall Diagnostics business, particularly its immunodiagnostics unit.
QIAGEN (QGEN) Gains from FDA's EUA for Antibody Total Test
by Zacks Equity Research
QIAGEN's (QGEN) COVID-19 total antibody test processes up to 32 swab samples per hour.
Here's Why You Should Add Inogen (INGN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.
BD's (BDX) First Self-Collection HPV Screening Assay Gets CE Mark
by Zacks Equity Research
BD's (BDX) industry-first CE marked self-collection claim for HPV screening enables greater access to testing for women.
HCA Healthcare (HCA) to Divest Hospital for Better Liquidity
by Zacks Equity Research
HCA Healthcare (HCA) to sell Redmond Regional Medical Center, GA to AdventHealth for boosting financial solvency.
PRA Health's (PRAH) New Solution to Speed Up Drug Development
by Zacks Equity Research
PRA Health's (PRAH) tokenization solution can help in the generation of enhanced evidence for drug development through Synoma.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Bruker (BRKR) on its slew of product launches and potential in the BSI Nano Group.
Here's Why You Should Retain Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vince Surgical System. However, rise in production costs is a woe.
Here's Why You Should Buy Amedisys (AMED) Stock Now
by Zacks Equity Research
Investors are optimistic about Amedisys (AMED) on bright Personal Care prospects, and strategic acquisitions and partnerships.
Amedisys (AMED) to Buy VNA Hospice, Home Health, Expand in NE
by Zacks Equity Research
The acquisition is going to expand Amedisys' (AMED) presence in Omaha and Council Bluffs' healthcare communities.
Here's Why You Should Hold on to Illumina (ILMN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Illumina (ILMN), backed by its focus on partnerships and robust adoption of its products.
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD), owing to its potential in digital health and consistent high demand for its masks.
Medtronic (MDT) to Enhance Patient Care via Digital Portal
by Zacks Equity Research
Medtronic's (MDT) first patient-centric digital health platform is expected to provide better outcome for patients undergoing the company's SCS therapy.
Henry Schein (HSIC) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Henry Schein (HSIC) is optimistic about maintaining robust sales of PPE and COVID-19-related products.
Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.
Amedisys (AMED) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Growth in Home Health and Hospice along with recent innovation and acquisitions is expected to have contributed to Amedisys (AMED) top-line growth in Q1.
The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys
Biden Chips in $400B for Home Healthcare: Stocks to Watch
by Sapna Bagaria
Biden's support to expand access to long-term care services under Medicaid bodes well for companies providing home healthcare.
Why Is Amedisys (AMED) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.